HUTCHMED (China) (HMDCF) Liabilities and Shareholders Equity (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Liabilities and Shareholders Equity came in at $1.7 billion in Q2 2026, down 2.22% year-over-year from $1.8 billion in Q2 2025, and down 0.95% quarter-over-quarter from $1.8 billion in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Liabilities and Shareholders Equity for 12 consecutive years, with $1.7 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 2.22% year-over-year to $1.7 billion in Q2 2026; TTM through Jun 2026 was $5.3 billion, a 73.39% increase from a year earlier, with the FY2025 full-year figure at $1.8 billion, changed N/A from the prior year.
- Liabilities and Shareholders Equity was $1.7 billion for Q2 2026 at HUTCHMED (China), down from $1.8 billion in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $1.8 billion in Q2 2025 and troughed at $1.0 billion in Q4 2022.
- A 5-year average of $1.4 billion and a median of $1.3 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity declined 25.0% in 2022 and soared 40.85% in 2025, its largest moves.
- Over 5 years, Liabilities and Shareholders Equity stood at $1.0 billion in 2022, then rose by 26.04% to $1.3 billion in 2023, then retreated by 2.82% to $1.3 billion in 2024, then soared by 39.04% to $1.8 billion in 2025, then decreased by 0.95% to $1.7 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $1.7 billion (Q2 2026), $1.8 billion (Q4 2025), and $1.8 billion (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 210.97 Bn | 196.98 Bn | 7.24 Bn | 95.64 Bn |
| 2 | Gilead Sciences | 180.98 Bn | 177.80 Bn | 6.22 Bn | 49.36 Bn |
| 3 | Vertex Pharmaceuticals | 132.09 Bn | 124.24 Bn | 2.84 Bn | 27.42 Bn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.57 Bn | 3.93 Bn | 41.73 Bn |
| 5 | Argenx Se | 61.71 Bn | 56.53 Bn | 1.37 Bn | 10.03 Bn |
| 6 | Moderna | 54.60 Bn | 49.46 Bn | 52.00 Mn | 10.96 Bn |
| 7 | Alnylam Pharmaceuticals | 34.02 Bn | 30.71 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn | 32.09 Bn |
| 9 | Roivant Sciences | 29.76 Bn | 29.76 Bn | 1.16 Mn | 5.31 Bn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 1.74 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.74 Bn |
| Dec 31, 2025 | 1.75 Bn |
| Jun 30, 2025 | 1.78 Bn |
| Jun 30, 2024 | 1.26 Bn |
| Jun 30, 2023 | 1.30 Bn |
| Dec 31, 2022 | 1.03 Bn |
| Jun 30, 2022 | 1.19 Bn |
| Dec 31, 2021 | 1.37 Bn |
| Jun 30, 2021 | 1.27 Bn |
| Mar 31, 2021 | 693.12 Mn |
| Dec 31, 2020 | 724.12 Mn |
| Jun 30, 2020 | 525.56 Mn |
| Dec 31, 2019 | 465.12 Mn |
| Sep 30, 2019 | 454.09 Mn |
| Jun 30, 2019 | 495.21 Mn |
| Mar 31, 2019 | 539.30 Mn |
| Dec 31, 2018 | 532.12 Mn |
| Jun 30, 2018 | 577.94 Mn |
| Dec 31, 2017 | 597.93 Mn |
| Jun 30, 2017 | 344.70 Mn |